1888PressRelease.com
1888 PressRelease Home Sign In Sign Up Contact Us About Us Sitemap
30
Nov
2007

Little Rock, AR. Local Distributor Announces Today Intentions Of Selling StaphWash Nationally

Central USA Distributors, Inc. announces today that after establishing StaphWash in Arkansas they are seeking retailers nationally to distribute StaphWash for its ability to kill the potentially deadly Staph/MRSA bacteria on the skin.

100% guaranteed to kill Staph MRSA bacteria on contact!

(1888PressRelease) November 30, 2007 - StaphWash has no known side effects, and is now available to fight Staph/MRSA Bacteria.

It is not a drug. It is a skin cleanser. StaphWash uses multiple mechanisms of action to attack MRSA and other bacteria.

The manufacturer recently completed the first phase of field trials to evaluate StaphWash as an antibacterial skin cleanser. The results of this set of field trials, including clinical results, can be found on the Distributors website, http://www.staphwash.com.

StaphWash is for use on human skin, kills and removes Staph Bacteria including MRSA. It consistently kills 100% of the bacteria that causes Staph infections in controlled in-vitro testing according to the manufacturer, Phillips & Company. “Doctors and Pharmacists are now recommending StaphWash for killing the MRSA bacteria infection in boils and lesions,” said James Pate, owner of Central USA Distributors, Inc.

Staphylococcus aureus (Staph) bacteria has evolved, and common antibiotics are no longer effective in killing the stronger forms of this bacteria, called MRSA. Researchers have also found infections with methicillin-resistent Staphylococcus aureus among hospitalized patients.

A newer form of Staph-infection, known as CA-MRSA (community acquired or community associated Methicillin resistant staphylococcus aureus) has appeared with increasing frequency and is now epidemic within certain community populations and is spreading through prisons, gyms, and in urban neighborhoods.

What is the cost of MRSA? MRSA patients stayed in the hospital two and a half times longer than patients without the anti-biotic resistant infection and patients are four times more likely to die, according to a recent report by the Pennsylvania Health Care Cost Containment Counsel. The Pennsylvania agency found 13,722 patients with MRSA, Based on 2004 data, the latest available. Hospital Charges for Patients with MRSA were three times higher than charges for patients without the infections.

“The prevalence of MRSA in every hospital in the U.S. poses a very serious health risk to patients who are unwittingly exposed to these superbugs,” said Lisa McGiffert, Director of consumers Union’s Stop Hospital Infections campaign.

For further information, Contact:

Central USA Distributors, Inc.
Toll Free at 1-800-918-9443
http://www.staphwash.com

or

Dr. Howard Phillips 580-746-2430

 
 

Visit Our Site

Contact Information

James Pate

Central Usa Distributors , Inc. Pamela Butler

72206

Voice: 501-888-6777

Visit our Site